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Abstract 1 
Background  2 
Additional vector control tools (VCTs) are needed to supplement insecticide-treated nets (ITNs) and 3 
indoor residual spraying (IRS) to achieve malaria elimination in many settings. To identify options for 4 
expanding the malaria vector control toolbox, we conducted a systematic review of the availability and 5 
quality of the evidence for 21 malaria VCTs, excluding ITNs and IRS.  6 
Methods  7 
Six electronic databases and grey literature sources were searched from January 1, 1980 to September 28, 8 
2015 to identify systematic reviews, Phase I-IV studies, and observational studies that measured the effect 9 
of malaria VCTs on epidemiological or entomological outcomes across any age groups in all malaria-10 
endemic settings. Eligible studies were summarized qualitatively, with quality and risk of bias 11 
assessments undertaken where possible. Of 17,912 studies screened, 155 were eligible for inclusion and 12 
were included in a qualitative synthesis.  13 
Results 14 
Across the 21 VCTs, we found considerable heterogeneity in the volume and quality of evidence, with 15 
seven VCTs currently supported by at least one Phase III community-level evaluation measuring 16 
parasitologically-confirmed malaria incidence or infection prevalence (insecticide-treated clothing and 17 
blankets, insecticide-treated hammocks, insecticide-treated livestock, larval source management (LSM), 18 
mosquito-proofed housing, spatial repellents, and topical repellents). The remaining VCTs were 19 
supported by one or more Phase II (n=13) or Phase I evaluation (n=1). Overall the quality of the evidence 20 
base remains greatest for LSM and topical repellents, relative to the other VCTs evaluated, although 21 
existing evidence indicates that topical repellents are unlikely to provide effective population-level 22 
protection against malaria.  23 
Conclusions  24 
Despite substantial gaps in the supporting evidence, several VCTs may be promising supplements to ITNs 25 
and IRS in appropriate settings. Strengthening operational capacity and research to implement 26 
underutilized VCTs, such as LSM and mosquito-proofed housing, using an adaptive, learning-by-doing 27 
approach, while expanding the evidence base for promising supplementary VCTs that are locally tailored, 28 
should be considered central to global malaria elimination efforts.  29 
Introduction 30 
Great advances have been made in malaria control and elimination, with a 37% global decline in malaria 31 
incidence during 2000-2015 (Global Malaria Programme, 2015). New targets include the elimination of 32 
malaria from at least 35 countries by 2030 (Global Malaria Programme, 2017), with renewed calls for 33 
eradication within a generation (Gates and Chambers, 2015). In sub-Saharan Africa (SSA), vector control 34 
with insecticide-treated nets (ITNs) and indoor residual spraying (IRS) has averted an estimated 524 35 
million malaria cases since 2000 (Global Malaria Programme, 2015). However, after an extraordinary 36 
period of success in global malaria control, progress has stalled with 216 million malaria cases in 2016, 37 
up 5 million cases from 2015 (Global Malaria Programme, 2017). There remain important obstacles to 38 
achieving and sustaining progress towards elimination, including operational inefficiencies that lead to 39 
low effective coverage (Bhatt et al., 2015), insecticide resistance (Ranson and Lissenden, 2016), and 40 
residual transmission mediated by mosquito behaviours such as outdoor biting and resting, feeding upon 41 
animals, and early exit from houses immediately after entering, which are not effectively targeted by 42 
ITNs and IRS (Killeen; 2014, Govella and Ferguson, 2012).  43 
 44 
To achieve malaria elimination goals in the face of such challenges, what evidence-based vector control 45 
tools (VCTs) can national malaria control and elimination programs access today or within the next 46 
decade to supplement ITNs and IRS? To date, ITNs and IRS are the only VCTs to have been 47 
recommended for wide-scale implementation by the World Health Organization (WHO), while larval 48 
source management (LSM) and personal protection measures against mosquitoes are recommended in 49 
some settings (World Health Organization, 2015). Recognising the need for additional VCTs, WHO 50 
recently established mechanisms for expedited vector control recommendations, including new technical 51 
expert panels (Malaria Policy Advisory Committee, 2015; WHO Vector Control Advisory Group, 2013) 52 
and the Innovation to Impact (I2I) initiative to support VCT development and access (Innovation to 53 
Impact (I2I), 2016). Recent calls for novel vector control interventions with proven effectiveness elevated 54 
the global demand for new VCTs (World Health Organization, 2017; malERA Refresh Consultative Panel 55 
on Tools for Malaria Elimination, 2017). Here, to guide the identification of promising VCTs to expand 56 
the vector control toolbox for malaria elimination, we conducted a systematic review to collate published 57 
and unpublished evidence on the effect of selected VCTs on confirmed clinical malaria and malaria 58 
infection in people of any ages and on Anopheles-specific entomological outcomes in malaria-endemic 59 
regions. This is the first study to collate systematically the evidence across the spectrum of malaria vector 60 
control, excluding ITNs and IRS. Innovations in ITN and IRS technologies are also important 61 
contributions to the vector control toolbox (e.g. new active ingredients, insecticide combinations, and 62 
application technologies, among others) with significant product development and evaluation efforts 63 
underway but are outside the scope of this review (Innovative Vector Control Consortium, 2016; 64 
Wagman et al., 2018). 65 
 66 
Methods  67 
We conducted a systematic review of the literature to summarize the availability and quality of the 68 
evidence for 21 malaria VCTs, excluding ITNs and IRS (Table 1). We followed guidelines of the 69 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (Additional File 1) 70 
(Wilson et al., 2015). The candidate VCTs for evaluation were selected through consultation with experts 71 
(including a meeting held on June 1-3, 2015 in San Francisco, US) and the review of policy documents 72 
(WHO Vector Control Advisory Group, 2013; WHO Vector Control Advisory Group, 2014). 73 
 74 
[Insert Table 1 here] 75 
 76 
Eligibility criteria 77 
Studies were included that evaluated any VCT targeting Anopheles mosquitoes in Table 1 and that met 78 
the eligibility criteria described in Table 2. Eligible study designs were categorized as observational, 79 
Phase I, Phase II, or Phase III studies. Observational studies included those with case-control, cohort or 80 
cross-sectional designs. Phase I studies were defined as laboratory assays to determine the mode of 81 
action. Phase II were defined as semi-field, experimental hut, and small-scale field studies, generally with 82 
entomological outcomes. Finally, Phase III studies were defined as trials measuring the efficacy of the 83 
VCT against epidemiological outcomes under optimal conditions (Wilson et al., 2015). Categories based 84 
on level of evidence were used since level of evidence is the basis for WHO policy recommendation.  85 
 86 
[Insert Table 2 here] 87 
 88 
Search strategy and selection criteria 89 
PubMed; EMBASE; LILACS; the Cochrane Infectious Diseases Group Specialized Register; Cochrane 90 
Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; and the Meta-91 
Register of Controlled Trials (mRCT) were searched for studies published in English from January 1, 92 
1980 to September 28, 2015 with the search terms described in Additional File 2. Search dates were 93 
restricted because systematic reviews included in this review captured the historical evidence on older 94 
VCTs, including LSM. Additionally, we searched reference lists of identified studies and contacted 95 
authors and field experts for unpublished data. To identify studies in progress, we searched the 96 
ClinicalTrials.gov registry. YAW and SH independently screened titles and abstracts, followed by full-97 
text screening of relevant studies for eligibility using a standard form in Qualtrics (Qualtrics, Provo, UT). 98 
Disagreements were resolved by LST.  99 
 100 
Data abstraction 101 
Study characteristics (including participants, intervention, control group, outcomes, and sample size, as 102 
applicable) and findings were double-entered into a standard form in Microsoft Excel by YAW and 103 
verified by LST. Since we aimed to assess evidence availability, not VCT efficacy, we did not combine 104 
studies in a meta-analysis. Instead, for each VCT we summarized the current evidence by the number and 105 
type of completed studies and, where possible, stratified this information by outcome. We presented in 106 
tables all eligible studies for every VCT, except for VCTs with a recent (≤5 years old) high-quality 107 
systematic review (Measurement Tool to Assess Systematic Reviews (AMSTAR) (Shea et al., 2007) 108 
score ≥50%; see below), for which we presented only the systematic review (Wilson et al., 2015). 109 
 110 
Quality of systematic reviews and risk of bias in Phase III studies 111 
The quality of systematic reviews was assessed using the AMSTAR tool (Shea et al., 2007). Risk of bias 112 
for randomized controlled trials (RCTs), controlled before-and-after studies (CBA), cross-over studies, 113 
and interrupted time-series studies was assessed using the Effective Practice and Organization of Care 114 
(EPOC) tool (Effective Practice and Organisation of Care (EPOC), 2015). Risk of bias was not assessed 115 
for Phase I, Phase II, or observational studies due to wide heterogeneity in study designs. We did not 116 
perform a statistical test for publication bias because we did not conduct any meta-analyses. 117 
 118 
Results 119 
The search results yielded 17,912 unique studies after removing duplicates (Figure 1). A total of 155 120 
studies met the eligibility criteria and were included in the qualitative synthesis; these were of the 121 
following designs: systematic reviews (n=7); Phase III (n=7), Phase II (n=76), and Phase I (n=54) 122 
experimental studies; and cross-sectional (n=7), case-control (n=3), and cohort (n=1) observational 123 
studies (Figure 2, Additional File 3). Methodological quality was variable across the seven eligible 124 
systematic reviews, with AMSTAR scores ranging from 18% to 100% (Additional File 4A). The 125 
systematic reviews of LSM (n=2), mosquito-proofed housing (n=1), and topical repellents (n=1) were 126 
determined to be of the highest quality (AMSTAR scores ≥50%), while those of spatial repellents (n=2) 127 
and zooprophylaxis (n=1) were judged to be of lower quality. Of the 21 VCTs evaluated, we identified 128 
seven with one or more completed Phase III study, including some that were included in systematic 129 
reviews: LSM, insecticide-treated clothing and blankets, insecticide-treated hammocks, insecticide-130 
treated livestock, mosquito-proofed housing, spatial repellents, and topical repellents; with recent, high-131 
quality systematic reviews available for LSM, mosquito-proofed housing, and topical repellents (Table 3). 132 
 133 
[Insert Figure 1 here] 134 
 135 
[Insert Figure 2 here] 136 
 137 
[Insert Table 3 here] 138 
 139 
VCTs with a recent systematic review 140 
Larval source management (LSM): A 2013 Cochrane review compared biological control with 141 
larvivorous fish to biological control without larvivorous fish (Walshe et al., 2013). No eligible studies 142 
included in this review measured malaria incidence, entomological inoculation rate (EIR), or adult vector 143 
density (Table 3). Nine quasi-experimental studies measured larval mosquito density, with variable 144 
effects. A second 2013 Cochrane review compared LSM (excluding biological control with larvivorous 145 
fish) with no LSM (Tusting et al., 2013). Compared to the control, LSM reduced malaria incidence by 146 
74% in two cluster RCTs, but there was no consistent effect on malaria incidence in three CBA studies. 147 
GRADE quality (Atkins et al., 2004) of evidence ranged from very low to moderate. Parasite prevalence 148 
was reduced by 89% in another cluster-RCT and by an average of 68% in five CBA studies. GRADE 149 
quality of evidence was assessed to be moderate for both subgroups.  150 
 151 
Mosquito-proofed housing: A 2015 systematic review included one Phase III RCT and four observational 152 
studies in a meta-analysis comparing screened with unscreened housing, in which findings on the effect 153 
on clinical malaria, malaria infection, and anaemia in children were inconsistent (Table 3) (Tusting et al., 154 
2015). A further 15 observational studies were included in a meta-analysis comparing ‘modern’ housing 155 
(e.g. brick or cement walls and metal roofs) with ‘traditional’ housing (e.g. mud walls, thatched roofs, 156 
open eaves, and no screening) (Tusting et al., 2015). Modern housing was associated with a 45-65% 157 
lower odds of clinical malaria and 47% lower odds of malaria infection, compared to traditional housing, 158 
although the GRADE quality of evidence was assessed to be very low. 159 
 160 
Topical repellents: In a systematic review of experimental studies comparing topical repellents with no 161 
repellent or placebo repellents (Wilson et al., 2014), the risk of P. falciparum malaria or infection was 162 
reduced by 18% in six RCTs and one CBA. P. vivax malaria or infection was reduced by 20% in five 163 
RCTs and one CBA, compared to the control, but neither reduction was statistically significant. EPOC 164 
risk of bias in the included studies ranged from low to unclear (Table 3).  165 
 166 
Other VCTs with a Phase III evaluation 167 
Insecticide-treated clothing and blankets: Malaria incidence was measured in two RCTs with low to 168 
moderate risk of bias, where the effect of insecticide-treated clothing and blankets ranged from an 81% 169 
decrease to no effect, compared to the control (Table 3) (Macintyre et al., 2003; Rowland et al., 1999). 170 
Outcomes assessed by the four Phase II studies included parasite prevalence (n=2) and adult mosquito 171 
mortality (n=2) (Additional File 3B).  172 
 173 
Insecticide-treated hammocks: Malaria incidence and parasite prevalence were measured in two Phase III 174 
RCTs, with EPOC risk of bias for both studies assessed to be low (Table 3). In Venezuela, insecticide-175 
treated hammocks reduced malaria incidence by 56% and parasite prevalence by 83%, compared to the 176 
control (Magris et al., 2007), and in Vietnam a greater reduction in malaria incidence and parasite 177 
prevalence was observed in the intervention arm than in the control (footnote to Table 3) (Thang et al., 178 
2009). One Phase II study measured adult An. gambiae mortality, hut entry, and blood feeding inhibition 179 
(Additional File 3C).  180 
 181 
Insecticide-treated livestock: Malaria incidence and parasite prevalence were measured in one Phase III 182 
cross-over study, with EPOC risk of bias assessed to be moderate, in which insecticide-treated livestock 183 
reduced malaria incidence by 31-56% and parasite prevalence by 40-54% compared to the control, though 184 
the effect was not consistently significant (Table 3) (Rowland et al., 2001). Entomological outcomes 185 
measured in five Phase II studies included adult mosquito mortality and blood feeding preference 186 
(Additional File 3C).  187 
 188 
Spatial repellents: Two systematic reviews included laboratory and Phase II field studies only, with no 189 
meta-analyses (Table 3) (Lawrence and Croft, 2004; Ogoma et al., 2012). No eligible studies measured 190 
the effect of spatial repellents on malaria incidence. Parasite prevalence was measured in two RCTs, with 191 
the EPOC risk of bias assessed to be low for both studies, and in one cross-sectional study. In the RCTs, 192 
transfluthrin coils reduced parasite prevalence by 77% compared to long-lasting insecticide-treated nets 193 
(LLINs) alone and by 94% when combined with LLINs, compared to no intervention in China (Hill et al., 194 
2014); metofluthrin mosquito coils reduced parasite prevalence by 52% compared to a placebo in 195 
Indonesia (Syafruddin et al., 2014). Entomological outcomes measured in 23 Phase II studies and one 196 
Phase I study included human biting rate (HBR), adult mosquito mortality, and repellency (Additional 197 
File 3C).  198 
 199 
VCTs with no Phase III evaluation 200 
Fourteen VCTs had Phase I, II, and/or observational evidence only: adult sterilization by contamination, 201 
attractive toxic sugar baits (ASTBs), other attract-and-kill mechanisms, biological control of adult 202 
vectors, eave tubes and eave baffles, endectocide administration in humans, endectocide administration in 203 
livestock, genetic modification, insecticide-treated durable wall linings, insecticide-treated fencing, 204 
larvicide application by autodissemination, push-pull systems, space spraying (ground application), and 205 
zooprophylaxis (Figure 2, Additional File 3C, Additional File 3D).  For these VCTs we included a total of 206 
103 studies, comprising 42 Phase II, 51 Phase I, and 10 observational studies. All VCTs had at least one 207 
eligible Phase II study, except endectocide administration in humans. Three VCTs had at least one 208 
eligible observational study: endectocide administration in humans, spatial repellents, and 209 
zooprophylaxis. For zooprophylaxis, we also identified one systematic review (AMSTAR score 18%), 210 
which reported no meta-analysis (Donnelly et al., 2015). Entomological outcomes were measured for all 211 
VCTs, while epidemiological outcomes were measured for two VCTs only (space spraying and 212 
zooprophylaxis). 213 
 214 
Discussion 215 
To address the challenges of insecticide resistance and residual transmission, strengthen malaria vector 216 
control, and maintain progress towards elimination, additional malaria vector control tools are needed. In 217 
this systematic review assessing the availability and quality of evidence for 21 supplementary VCTs, we 218 
included 155 studies dating from January 1, 1980 to September 28, 2015. This is the first study to collate 219 
evidence systematically across the malaria vector control toolbox beyond ITNs and IRS. Our study 220 
highlights the expanding pipeline of research into supplementary VCTs, while identifying substantial 221 
heterogeneity in the availability and quality of the evidence required by WHO to provide normative 222 
guidance on implementation (i.e. standardized epidemiological data from Phase III trials in multiple 223 
settings) (WHO Vector Control Advisory Group, 2013; Malaria Policy Advisory Committee, 2012).    224 
 225 
For each VCT, we summarized the current evidence by the number and quality of studies and stratified 226 
this information by outcome where possible since this information forms the basis of WHO policy 227 
considerations. Within this framework, the evidence base was the most extensive for LSM and topical 228 
repellents, which both have multiple published Phase III evaluations and recent systematic reviews 229 
assessed to be of high methodological quality. While the evidence for LSM was assessed to be of very 230 
low to moderate quality (Tusting et al., 2013), combinations of larviciding and environmental 231 
management have been effective in reducing malaria transmission in certain eco-epidemiological settings 232 
in Africa and Asia and larviciding has been recommended by WHO as a supplementary intervention in 233 
SSA since 2013 (Global Malaria Programme, 2015). This recommendation is limited to discrete settings 234 
where habitats are relatively ‘few, fixed, and findable’; far narrower than settings in high-income 235 
countries where larviciding is used routinely and successfully for mosquito and disease control (Global 236 
Malaria Programme, 2015). In contrast, the evidence for topical repellents is of relatively high quality 237 
(Wilson et al., 2014) but indicates that topical repellents are unsuitable as a large-scale public health 238 
intervention, although they can provide individual protection against mosquitoes (Wilson et al., 2014). 239 
We identified five further VCTs with at least one Phase III evaluation with epidemiological outcomes: 240 
insecticide-treated clothing and blankets, insecticide-treated hammocks, insecticide-treated livestock, 241 
mosquito-proofed housing, and spatial repellents. These VCTs offer additional options for supplementing 242 
ITNs and IRS, often with complementary modes of action. Further Phase III community level trials will 243 
help to clarify their roles in malaria vector control in different epidemiological settings (Killeen, 2014; 244 
Lobo NF et al. 2014; Pinder et al., 2016). 245 
 246 
Our assessment of evidence was based on study design and outcomes, but in the future it may be 247 
necessary to consider evidence complementary to standard epidemiological assessments (Vontas et al., 248 
2014). First, making recommendations across diverse transmission settings and local vector ecologies is 249 
difficult; what works in one or two settings may not work in all settings. Growing understanding of the 250 
genetic diversity among Anopheles further contributes to this complexity (The Anopheles gambiae 1000 251 
Genomes Consortium, 2017). Trends in malaria transmission and performance of VCTs are also 252 
confounded by longer-term changes in environmental and infrastructural landscapes and climate (Snow et 253 
al., 2017). Although Cochrane reviews remain the gold standard in evidence-based policy, it is often 254 
inappropriate to combine findings from studies across different eco-epidemiological settings when VCT 255 
efficacy is tied to local transmission ecology (Walshe et al., 2013; Tusting et al., 2013). Second, some 256 
emerging VCTs remain years away from accumulating a full dossier of epidemiological evidence, and 257 
although further Phase III studies are planned (Thomas M et al., 2015), nearing completion (Mtove et al., 258 
2016), or recently concluded (Homan et al., 2017), we identified fourteen VCTs for which no Phase III 259 
epidemiological data were available within the search dates. Demonstrating protection against disease 260 
and/or infection is critical before any VCTs can be recommended for large-scale deployment (Wilson et 261 
al., 2015). However, in some circumstances, evidence of effect might be built by adopting underutilised 262 
VCTs as supplementary interventions within a ‘learning-by-doing’ framework. This iterative, adaptive 263 
approach involves the incorporation of rigorous monitoring and evaluation of epidemiological and 264 
entomological outcomes in control and intervention areas to support the gradual scale-up of additional 265 
VCTs within existing programme infrastructure, such as through adaptable Phase IV effectiveness studies 266 
(Killeen, 2014; Wilson et al., 2015; Global Malaria Programme, 2014). For example, while only one RCT 267 
of house screening for malaria control has been completed (Kirby et al., 2009), a large body of 268 
observational evidence suggests that screened housing is associated with reduced malaria risk and 269 
national malaria control programs are encouraged to explore opportunities to build ‘healthier’ housing 270 
(Roll Back Malaria, 2015). This approach would also allow for a more rapid expansion of the evidence 271 
base across a wider diversity of eco-epidemiological settings to inform locally-tailored solutions as well 272 
as iteration over time as the transmission landscape changes.   273 
 274 
Direct transition to Phase IV ‘learning-by-doing’ approaches are controversial and inappropriate for 275 
VCTs with a poor or absent evidence base (Wilson et al., 2015). The history of ITNs and IRS 276 
demonstrates varying routes to establishing effectiveness against malaria disease or infection; ITNs 277 
underwent rigorous evaluation through Phase III RCTs (Darriet et al., 1984), while IRS effectiveness was 278 
established decades before evaluation in RCTs (Sadasivaia et al., 2007). Given adequate funding, 279 
promising new VCTs should reach approval far faster than ITNs, but depending on the entomological 280 
mode of action, efficacy of a VCT in one ecological setting is not always guaranteed elsewhere. Recent 281 
examples illustrate the importance of demonstrating efficacy against epidemiological as well 282 
entomological outcomes. Topical repellents reduce vector biting, but it took a cluster RCT with 283 
epidemiological outcomes to show their unsuitability as a generalizable public health intervention due to 284 
the high user compliance required (Messenger, 2012). Conversely, odour baited traps have recently been 285 
shown to reduce malaria infection prevalence in a rigorous RCT, but entomological data from that study 286 
suggest caution before deploying this VCT at scale in different settings since the traps were largely 287 
effective against An. funestus only (Homan et al., 2017).36 Such information may be obtainable through 288 
‘learning-by-doing’ evaluations, as long as evaluations of outcomes are of high quality. Research 289 
institutions will need to support control programs in design, technical capacity, and analysis to ensure 290 
meaningful findings are obtained from Phase IV effectiveness evaluations. A recent call for more 291 
adaptive strategies responding to shifting transmission also highlights the need for optimizing 292 
combinations of interventions to maximize impact and mitigate the risk of insecticide resistance (malERA 293 
Refresh Consultative Panel on Tools for Malaria Elimination, 2017).  294 
 295 
Despite limited evidence on their efficacy against malaria, the fourteen VCTs with no complete Phase III 296 
evaluation offer diverse modes of action to complement those of ITNs and IRS within a comprehensive 297 
intervention package. Some may only be suitable for niche application, for example, insecticide-treated 298 
clothing may be effective for individuals working outdoors at night, but not as a general public health 299 
intervention. Others such as insecticide-treated durable wall linings (which are impregnable with 300 
alternative insecticides to those used for IRS) might reduce reliance on the main classes of insecticides 301 
currently available for ITNs and IRS; a multi-country Phase III evaluation is currently underway 302 
(Messenger, 2012). Similarly, administration of endectocides such as ivermectin to people or livestock 303 
could circumvent insecticide resistance and target zoophagic behaviours in vectors, although 304 
epidemiological effect remains to be demonstrated (Chaccour et al., 2015; Foy et al., 2011). Some 305 
emerging VCTs might reduce transmission by vectors biting outdoors, including larvicide application by 306 
autodissemination using pyriproxyfen, which targets immature mosquitoes regardless of adult biting and 307 
resting behaviour (Mbare et al., 2014). Some emerging VCTs exploit vulnerability in alternative vector 308 
life stages to those targeted by ITNs and IRS. ATSBs, which target sugar feeding, consistently reduced 309 
adult mosquito density and HBR in Phase II studies in Israel, Mali, and the USA. However, Phase III 310 
trials of ATSBs with epidemiological outcomes are certainly needed. Genetic modification of mosquitoes 311 
aims to suppress populations thereby reducing vectorial competence (Alphey and Alphey, 2014), but our 312 
review highlights how such approaches have yet to progress fully beyond laboratory evaluations.  313 
 314 
Overall the expansion of research on supplementary VCTs is encouraging, but arguably the first step to 315 
strengthening vector control for malaria elimination is to improve operational capacity to deliver and 316 
sustain existing interventions effectively (Brady et al., 2016). For example, major inefficiencies persist 317 
within LLIN delivery systems across SSA, limiting population access (Bhatt and Gething, 2014). There 318 
are also opportunities to explore new or improved delivery mechanisms for existing supplementary 319 
interventions, such as aerial application of larvicides (Knapp et al., 2015). Some VCTs may not be highly 320 
effective individually, but could potentially be highly effective when used in combinations. The malERA 321 
updated research agenda highlights this need for optimizing combinations of interventions to maximize 322 
impact and mitigate the risk of insecticide resistance (malERA Refresh Consultative Panel on Tools for 323 
Malaria Elimination, 2017). Use of mathematical models could help to address such questions, where no 324 
epidemiological evidence is available (Kiware et al., 2017). Critical to improving vector control is the 325 
development of strong local entomological capacity (Mnzava et al., 2014), together with a much more 326 
significant focus on community engagement and effective integration of control across vector-borne 327 
diseases and government sectors (Brady et al., 2016; World Health Organization, 2009; World Health 328 
Organization, 2017).  329 
 330 
Our study has several limitations. First, our VCTs of interest were selected a priori through expert 331 
consultation and are not an exhaustive list. Second, our search was restricted to English language papers 332 
only, potentially excluding experiences from some regions. Third, we did not combine data across studies 333 
in a meta-analysis, precluding evaluation of effect on entomological and epidemiological outcomes and 334 
statistical tests for publication bias. Fourth, for studies with entomological outcomes there was no 335 
mechanism to standardize outcomes and assess how heterogeneity in the choice of control affected study 336 
findings. Fifth, this review focused on individual interventions and did not consider the potential benefits 337 
of combining two or more of the new VCTs in communities already using ITNs and/or IRS. Finally, we 338 
did not assess methodological quality and risk of bias in Phase I and II studies due to heterogeneity in 339 
study design.  340 
 341 
In conclusion, our review highlights the expanding pipeline of research into new and underutilized 342 
approaches to malaria vector control and the critical need to prioritize and fund robust evaluation of 343 
supplementary VCTs. Despite substantial gaps in the supporting evidence, several VCTs are promising 344 
supplements to ITNs and IRS. Strengthening operational capacity to implement and evaluate 345 
underutilized VCTs, such as LSM and mosquito-proofed housing, while expanding the evidence base for 346 
newer VCTs through strategic assessment of existing evidence and rigorous epidemiological evaluation, 347 
should be central to global malaria control and elimination efforts. A practical, program-oriented research 348 
agenda to evaluate where, when, and in what combination to use these supplemental VCTs should be 349 
developed and prioritized for funding and implementation in the near-term. Future research should also 350 
assess the cost, cost-effectiveness, scalability, and availability of supplemental VCTs to inform vector 351 
control strategies and intervention selection as countries and regions accelerate toward elimination.   352 
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  559 
17952 records identified 
through  database searching
17912 records after duplicates removed
17912 records screened
692 full-text articles excluded
570 does not evaluate a vector control tool of interest
42 no entomological or epidemiological outcomes of interest
27 non-systematic review 
16 perspective piece or news article 
16 model
15 study design does not meet eligibility criteria
2 repeat of study data or population
1 not in English
2 no control group
1 full-text unavailable
847 full-texts articles 
assessed for 
eligibility 
23 additional records 
identified through other 
sources*           
17065 records 
excluded
155 studies eligible 
for inclusion in the 
qualitative synthesis 
Figure 1. Study flow for a systematic review of the evidence for 21 malaria vector control tools
*Other sources: reference lists of included studies
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Figure 2. Frequency of eligible studies of 21 malaria vector control tools (VCTs), stratified by study design. A: studies 
with any outcome of interest; B: studies with diagnostically confirmed malaria incidence or prevalence. †Only systematic 
reviews with AMSTAR (A Measurement Tool to Assess Systematic Reviews14) scores of ≥50% are included. *For topical 
repellents, larval source management and mosquito-proofed housing, the frequency of studies represents all eligible studies 
within the referenced systematic review. For all other VCTs, the frequency of studies represents all eligible studies within the 
present review. 
Table 1. Description of malaria vector control tools (VCTs) included in the review 
VCT* Description 
Primary mode(s) of action 
against malaria vectors 
Interventions targeting immature mosquitoes 
Larval source management 
(LSM) 
Management of potential larval habitats to prevent the development of immature 
mosquitoes into adults; includes habitat modification and manipulation; biological control 
with natural enemies of mosquitoes; aerial and ground-based larviciding.  
Reduced adult emergence 
and density 
Interventions targeting adult mosquitoes 
Adult sterilization by 
contamination  
Sterilization of adult mosquitoes through contact with pyriproxyfen, using delivery 
mechanisms other than ITNs. 
Reduced adult reproduction 
and density  
Other attract-and-kill 
mechanisms  
Traps and targets that attract blood-seeking mosquitoes using a combination of odours from 
humans and other mammals (e.g. carbon dioxide, L-lactic acid, ammonia and short-chain 
fatty acids), some of which are treated with chemical or biological insecticides (e.g. 
pyrethroids organophosphates, entomopathogenic fungi). 
Increased adult mortality 
Attractive toxic sugar baits 
(ATSB) 
Lethal traps that exploit sugar-feeding behaviour to attract mosquitoes using sugar and that 
contain insecticides (e.g. boric acid). 
Reduced adult survival and 
density 
Biological control of adult vector 
capacity/longevity 
Infection of adult mosquitoes with bacteria (e.g. Wolbachia spp) or entomopathogenic fungi 
to reduce longevity and/or up-regulate immune genes. 
Reduced adult survival and 
infection rates 
Eave tubes and eave baffles  
A variety of different eave (space between the roof and walls of a house or structure) 
modifications that kill mosquitoes with traps or insecticides when they try to enter or exit 
from those houses. 
Reduced adult survival and 
density 
Endectocide administration in 
humans  
Mass administration to humans of a systemic insecticide, sometimes described as an 
endectocide (e.g. ivermectin). 
Reduced adult survival and 
density 
Endectocide administration in 
livestock 
Mass administration to livestock of an endectocide (e.g. ivermectin, fipronil, eprinomectin) 
to kill zoophagic Anopheles.  
Reduced adult survival and 
density 
Genetic modification  
Mass release of mosquitoes, which are genetically modified (e.g. homing endonuclease 
genes (HEG) and RNA interference (RNAi); radiation-or chemo-sterilized males (sterile 
insect technique, SIT)). 
Reduced adult reproduction 
and density and/or reduced 
competence as the primary 
host for malaria parasites 
Insecticide-treated clothing and 
blankets 
Clothing and/or blankets treated with an insecticide (e.g. permethrin)  
Reduced adult survival and 
density, as well as human 
exposure to biting  
Insecticide-treated durable wall 
linings  
Thin, durable sheets of insecticide-treated cloths that cover interior wall surfaces; 
insecticides remain efficacious for a period of three to four years 
Reduced adult survival and 
density 
Insecticide-treated fencing Insecticide-treated netting used as fencing around livestock enclosures 
Reduced adult survival and 
density 
Insecticide-treated hammocks  Hammocks treated with an insecticide (e.g. permethrin)  
Reduced adult survival and 
density, as well as human 
exposure to biting  
Insecticide-treated livestock  
Application of topical insecticide (e.g. pyrethroids) or entomopathogenic fungus to 
livestock to kill zoophilic mosquitoes 
Reduced adult survival and 
density 
Mosquito-proofed housing  
Houses with features that reduce mosquito house entry (e.g. use of modern wall, floor and 
roof materials, use of insecticide-treated or untreated door and window screens, presence of 
a ceiling). 
Reduced human exposure to 
biting mosquitoes 
Push-pull systems 
The simultaneous use of attractive and repellent volatiles (e.g. baited trap near home with 
insecticide-treated fabric in eaves). 
Reduced adult survival and 
density, as well as human 
exposure to biting 
Space spraying (ground 
application) 
Liquid insecticide (e.g. pyrethroids, malathion) dispersed as fine droplets in the air (either 
thermal or cold fog) using hand-held or vehicle-mounted devices; can be used indoors or 
outdoors. Includes targeted spraying of male mating swarms. 
Reduced adult survival and 
density 
Spatial repellents  
Products that release chemical active ingredients into the air as vapours, which repel, 
incapacitate or kill adult mosquitoes (e.g. mosquito coils and emanators to release 
pyrethroids).  
Reduced human biting, 
increased adult mortality 
Topical repellents 
Insect repellent (e.g. DEET, citronella, picaridin, lemon eucalyptus) applied to the skin to 
provide personal protection from biting.  
Reduced human biting  
Zooprophylaxis  
Presence of animals/livestock to divert vector biting away from humans (which if applied at 
the individual level may also result in increased individual human risk, known as 
zoopotentiation).   
Reduced exposure of 
humans to infectious adult 
mosquitoes and mosquitoes 
to infectious human beings 
Interventions targeting immature mosquitoes via adults 
Larvicide application by 
autodissemination  
Delivery of larvicide (e.g. pyriproxyfen) to larval habitats by adult female mosquitoes that 
are exposed to contaminated artificial resting sites  
Reduced adult density 
*VCTs excluded from the study: adult mosquito traps with no kill mechanism, aerial application of larvicide or adulticide, electronic mosquito 
repellents, indoor residual spraying, insecticide-treated curtains and nets, insecticide-treated paint, insecticide-treated plastic sheeting in tents or 
in temporary shelters, insecticide-treated tents, live plants as spatial repellents, nanoparticles for larviciding. Additionally, studies of the 
insecticidal properties of compounds and formulations were excluded. 
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Table 2. Criteria for inclusion or exclusion of studies 
*Controlled before-and-after studies: if arms were comparable at baseline, there were at least two units per arm, 
follow-up periods were the same for the intervention and control arms, and baseline characteristics were comparable 
between arms.  
†Cross-over studies: if there was adequate allowance for washout (time between two intervention periods to allow 
the effect of the first intervention to be washed out). 
ǂInterrupted time-series studies: if data were collected during at least three time points pre- and post- follow-up, if no 
co-interventions were introduced after baseline data collection and if the intervention was implemented for a clearly 
defined period.  
§Phase III studies were differentiated from Phase II studies in being conducted in real-life settings (not semi-field or 
experimental hut systems) and having a minimum intervention period of one transmission season or year.  
¶Entomological inoculation rate (EIR): the number of bites by sporozoite-infected mosquitoes per person per unit 
time. 
ǁHuman biting rate (HBR): the number of host-seeking mosquitoes attempting to attack humans per person or house 
per time period.  
**Density measures other than HBR (e.g. number of mosquitoes per person, house or catch), measured directly using 
human landing catches or indirectly using light traps, knock-down catches or other methods of biting rate 
determination. 
††Secondary entomological outcomes, such as adult mosquito fecundity, adult mosquito fitness, adult emergence 
rates, knockdown post-exposure, blood-feeding inhibition, were included where reported in Phase I and II studies. 
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 Inclusion Criteria Exclusion Criteria 
Study design Systematic reviews of experimental studies Review articles   
Opinion papers  
Modelling studies 
 Phase III studies: randomized controlled (RCT), controlled 
before-and-after (CBA)*, cross-over†, interrupted time-
seriesǂ 
 Phase II studies§: small-scale, semi-field, experimental hut 
 Phase I studies: laboratory  
 Observational studies: case-control, cohort, cross-sectional 
Intervention  Any malaria vector control tool (VCT) targeting Anopheles 
mosquitoes described in Table 1  
Adult mosquito traps with no kill mechanism, 
electronic mosquito repellents, indoor residual 
spraying (IRS), insecticide-treated curtains and 
nets, insecticide-treated paint, insecticide-
treated plastic sheeting in tents or in temporary 
shelters, insecticide-treated nets (ITNs), 
insecticide-treated tents, live plants as spatial 
repellents, studies of the insecticidal properties 
of compounds and formulations  
Primary epidemiological 
outcomes 
Malaria incidence and infection prevalence in any age 
group, diagnostically confirmed by microscopy or rapid 
diagnostic test 
Malaria incidence and infection prevalence not 
diagnostically confirmed by rapid diagnostic 
test or microscopy 
Primary entomological 
outcomes 
Entomological inoculation rate (EIR)¶  
Human biting rate (HBR)ǁ  
Adult mosquito density metrics other than HBR**  
Secondary entomological 
outcomes†† 
Additional entomological outcomes appropriate to the 
intervention including adult mosquito fecundity, adult 
mosquito fitness, adult emergence rates, knockdown post-
exposure, blood-feeding inhibition 
 
Dates Studies published from January 1, 1980 to  September 28, 
2015 
Studies published before January 1, 1980 and 
after September 28, 2015 
